Fossamart Injection contains Fosaprepitant 150mg, a neurokinin-1 (NK1) receptor antagonist used primarily to prevent nausea and vomiting associated with chemotherapy. It works by blocking the action of substance P, a neuropeptide involved in triggering the vomiting reflex, thereby providing effective control of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). Administered intravenously, Fossamart Injection is typically given prior to chemotherapy treatment as part of a combination antiemetic regimen, often alongside corticosteroids and serotonin (5-HT3) receptor antagonists, to enhance its efficacy. Its rapid conversion to aprepitant in the body ensures prompt onset of action, making it suitable for patients undergoing highly emetogenic chemotherapy. The injection is generally well tolerated, with common side effects including fatigue, hiccups, and mild gastrointestinal disturbances. It is important to use Fossamart Injection under medical supervision, as dosage adjustments may be necessary based on the chemotherapy protocol and patient-specific factors such as liver function. By effectively reducing the incidence and severity of CINV, Fossamart Injection improves patient comfort and adherence to cancer treatment regimens, ultimately contributing to better therapeutic outcomes.